QRG Capital Management Inc. Increases Stake in Amgen Inc. $AMGN

Key Points

• QRG Capital Management Inc. increased its stake in Amgen by 7.2% in Q4, buying an additional 5,262 shares to hold 78,354 shares worth about $25,646,000.
• Amgen announced an additional $300 million investment to expand its U.S. manufacturing footprint in Juncos, Puerto Rico, part of nearly $2 billion of U.S. manufacturing investment over the last year to boost capacity and supply resilience.
• Amgen beat quarterly expectations with $5.15 EPS versus $4.77 consensus and $8.62B revenue, set FY2026 guidance of 21.700–23.100 EPS, and declared a quarterly dividend of $2.52 (annualized $10.08, yield ~3.1%; ex-dividend May 15).

QRG Capital Management Inc. increased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 78,354 shares of the medical research company's stock after purchasing an additional 5,262 shares during the period. QRG Capital Management Inc.'s holdings in Amgen were worth $25,646,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in AMGN. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the 4th quarter valued at $26,000. Olistico Wealth LLC bought a new stake in Amgen during the 4th quarter valued at $33,000. Cloud Capital Management LLC bought a new stake in Amgen during the 3rd quarter valued at $34,000. Ares Financial Consulting LLC bought a new stake in Amgen during the 4th quarter valued at $34,000. Finally, Saranac Partners Ltd bought a new stake in Amgen during the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced an additional $300 million investment to expand and modernize its U.S. manufacturing footprint in Juncos, Puerto Rico — part of nearly $2 billion of U.S. manufacturing investment over the last year; this strengthens capacity, supply resilience and long-term revenue support. AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
• Neutral Sentiment: Coverage of the Puerto Rico expansion by major outlets (Reuters, Quartz) highlights the same investment news — useful for validation but not new catalyst beyond the company release. Amgen to invest additional $300 million to boost US manufacturing footprint
• Neutral Sentiment: Health-care stocks were softer in afternoon trade, which can amplify selling in large-cap biopharma names like Amgen even when company fundamentals are unchanged. Sector Update: Health Care Stocks Softer in Afternoon Trading
• Neutral Sentiment: A Zacks note flagged increased investor attention to AMGN; this signals higher scrutiny/flow but doesn’t itself imply directional catalyst. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 from $351 and kept a Neutral rating — a modest cut but enough to pressure sentiment because it lowers upside expectations versus recent levels. Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

Analyst Ratings Changes

AMGN has been the subject of a number of recent analyst reports. TD Cowen reiterated a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Freedom Capital lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 12th. Sanford C. Bernstein lowered shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price target for the company. in a report on Tuesday, January 20th. Guggenheim lowered their price target on shares of Amgen from $351.00 to $340.00 and set a "neutral" rating for the company in a report on Monday. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $357.12.

Amgen Stock Down 1.8%

NASDAQ:AMGN opened at $323.85 on Tuesday. The firm's 50-day moving average price is $358.07 and its 200-day moving average price is $341.12. The company has a market capitalization of $174.78 billion, a PE ratio of 22.54, a P/E/G ratio of 3.24 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 0.90. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts predict that Amgen Inc. will post 22.28 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. Amgen's dividend payout ratio is currently 70.15%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.